Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

ASCO 2019 /
ZUMA-3: A study of KTE-X19 in adults with relapsed/refractory acute lymphoblastic leukaemia

31st May - 4th Jun 2019

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 06.06.19
Views: 742

Dr Bijal Shah - H. Lee Moffitt Cancer Center & Research Institute, Tampa, USA

Dr Bijal Shah talks to ecancer at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting about the end of phase I results from the ZUMA-3 study.

He emphasises that acute lymphoblastic leukaemia remains an unmet need as adult patients with primary refractory disease who relapse usually have poor outcomes.

Dr Shah explains the mode of action of KTE-X19, and notes its similarities to the CAR T cell therapy approved in B cell lymphoma.

In the 45 patients enrolled, Dr Shah states that 68% had three or more lines of therapy, as well as 42% of patients who had prior blinatumomab.

He reports the safety and efficacy data of this therapy (across doses) in which 68% of patients achieved high rates of complete remission (CR) or CR with incomplete hematologic recovery (CRI), which were all associated with a negative MRD.

Dr Shah believes this data is very encouraging and hopes that the phase II results of these study will be successful.

ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.

Previous conferences: highlights

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation